ARV Technologies
Startup
Advanced RNA Vaccine Technologies (ARV) has successfully established its RNA and LNP technologies since its founding in North Bethesda, Maryland, USA in 2021. Its first product, PanCOVAX, is a universal COVID19 mRNA vaccine that elicits potent neutralizing antibodies and T-cell immunity capable of providing broad protection against current and future variants of SARS-CoV-2, a platform also used as a strategy against other infectious diseases.
ARV has also developed an effective high-throughput platform to identify new compounds for RNA delivery in humans, and it has identified at least two sets of lipids that can effectively deliver RNA vaccines at 10-100 fold lower doses compared to currently marketed LNPs, but induce the same or higher immune responses.
In addition to developing HSV-2 and a cancer vaccine on its own, ARV is seeking to collaborate with other organizations to develop additional products.
ARV has also developed an effective high-throughput platform to identify new compounds for RNA delivery in humans, and it has identified at least two sets of lipids that can effectively deliver RNA vaccines at 10-100 fold lower doses compared to currently marketed LNPs, but induce the same or higher immune responses.
In addition to developing HSV-2 and a cancer vaccine on its own, ARV is seeking to collaborate with other organizations to develop additional products.
For conference programme and speaking opportunities:
Lauren Sheppard
lauren.sheppard@terrapinn.com
For sponsorship and exhibition opportunities:
Thomas Hall
thomas.hall@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events